Download Presentación de PowerPoint

Un centro integral de investigación
del cáncer en Red
FICUS
INSTITUTO DE BIOLOGÍA MOLECULAR Y CELULAR DEL
CÁNCER - CENTRO DE INVESTIGACIÓN DEL CÁNCER
IBMCC-CIC (CSIC – USAL)
Salamanca (Spain)
IBMCC-CIC MISSION AND VISION
The IBMCC-CIC is a joint enterprise between the Spanish Council
for Scientific Research (CSIC) and the University of Salamanca. It
is also a recognised Health Centre from the Castilla-León Health
System
IBMCC: Instituto
de Biología
Molecular y
Celular del
Cáncer
Centro
Sociosanitario de
Castilla y León
FICUS
www.cicancer.org
CARACTERÍSTICAS DEL CIC
INVESTIGACIÓN de EXCELENCIA
INTEGRACIÓN DE
INVESTIGACIÓN
•básica
•clínica
•aplicada
FICUS
CALIDAD
COMPETITIVIDAD
Búsqueda de
riqueza y bienestar
social
Objetivo:
EFICACIA en
investigación
oncológica
CARACTERÍSTICAS DEL CIC
INVESTIGACIÓN PUNTERA basada en los comprehensive
cancer centers
FICUS
Un CCC es un modelo restrictivo, hay menos de
cuarenta reconocidos en EEUU, y su requisito
fundamental
es
que
debe
desarrollar
investigación puntera -evaluada externamentede tres tipos: básica, clínica y aplicada. Ha
demostrado ser el más eficiente a la hora de
obtener los mejores resultados prácticos en
investigación oncológica.
The IBMCC-CIC intends to follow the model of the
USA Comprehensive Cancer Centers
GOALS:





FICUS


To create an environment of research excellence that could
compete in equal terms with other national and international cancer
centres.
To promote a synergistic cooperation among basic, clinical, and
translational laboratories.
To conduct a multifaceted study of the tumorigenic process at the
basic, translational, and clinical level.
To develop new diagnostic and prognostic tools of application to
cancer patients.
To put in motion technical and diagnostic facilities that favour
cancer diagnostics, prognostics and the development of new antitumoral therapies and treatments.
To promote interactions with other national and international
cancer centres as well as with the biopharmaceutical industry.
To train specialized personnel at the technical, graduate, and
postdoctoral level in molecular, translational, and clinical oncology.
ORGANIZATION: MANAGEMENT
IBMCC/CIC
Support
(personnel, funding)
USAL
CSIC
Sacyl
Health
Ctr
Graduate
program
Scientific advice
and reviews
Support
(personnel, funding)
FICUS
FICUS
Foundation Board
External Review
Committee
Other
FICUS
Education and
Science Regional
Ministry
Regional
Ministry of Health
ORGANIZATIONAL CHART
FICUS
FICUS
EXTERNAL
REVIEW
EXTERNAL SCIENTIFIC
REVIEW
COMMITTEE
COMMITTEE
IBMCC
DIRECTOR´S
OFFICE
MANAGEMENT OFFICE
ADMINISTRATION
RESEARCH UNITS
Administration
Ordering and accounting
Marketing and Communication
FICUS board
- CSIC
- USAL
- Junta Castilla León
- ISCIII
■ Joint Institute, CSIC-USAL
■ Health Center, Junta
Castilla León
TECHNICAL SERVICE
UNITS
Genomics & Proteomics
Molecular Diagnosis
Tumor Bank and Mol. Pathol.
DNA Bank, etc.
CORE FACILITIES
Media preparation
Reagent Store
Microscopy
Maintenance
FICUS
BASIC
RESEARCH
TRANSLATIONAL
RESEARCH
CLINICAL
RESEARCH
TECHNICAL PROGRAM
(Superior and FP-II)
GRADUATE PROGRAM
(USAL)
ORGANIZATION OF RESEARCH UNITS
PRINCIPAL
INVESTIGATORS
EMERGING GROUPS
RESEARCH UNITS
BASIC RESEARCH
FICUS
TRANSLATIONAL
RESEARCH
Junior scientists
Postdoctoral
Graduate students
Technical personnel
CLINICAL RESEARCH
Signal transduction
Oncogene characterization
Cell cycle regulation
Genomics and proteomics
Structural Biology, etc.
Molecular diagnostics
Tumour markers
Cellomics
Gene therapy
Anti-tumoral drugs, etc.
Molecular epidemiology
Genetic counselling
Oncogenes and disease
Clinical trials, etc.
Dr. Avelino Bueno
Dr. Eugenio Santos
Dr. Xosé R. Bustelo
Dr. Atanasio Pandiella
Dr. Sergio Moreno
Dr. Alberto Martín
Pendás
Dr. José M. Pereda
Dr. Pedro Lazo
Dr. Faustino Mollinedo
Dr. Rogelio Glez
Sarmiento
Dr. Isidro SánchezGarcía
Dr. Felipe X. Pimentel
Dr. Alberto Orfao
Dr. Jesús San Miguel
Dr. Juan Jesús Cruz
Dr. Alberto Gómez Alonso
Dr. Enrique de Álava
BASIC RESEARCH TEAMS
Avelino Bueno
Cell cycle analysis. Control of mitosis and checkpoint response in
eukaryotic cells
Xosé Bustelo
Small GTPases and cancer . Rho/Rac mediated signaling
Sergio Moreno
Cell cycle analysis. Cell division and cell differentiation.
Oncopharmacology. Drug target discovery
Atanasio Pandiella
Kinases in oncology. Signalling by receptor tyrosine kinases
Oncopharmacology. Novel drugs in haematological malignancies
Alberto M. Pendás
FICUS
Animal models in cancer. Chromosome instability and cancer
Eugenio Santos
Small GTPases and cancer . Ras mediated signalling
José María Pereda
Structural biology
TRASLATIONAL RESEARCH TEAMS
Rogelio Glez. Sarmiento
Clinical and molecular analysis of solid tumors and hereditary cancer
Pedro A. Lazo
Kinases in oncology. Signalling by serine-threonine kinases
Oncopharmacology. Ser-Thr kinase targets in oncology
Faustino Mollinedo
Cell death and cancer. Lipid rafts and death receptors
Oncopharmacology. Drug discovery and mechanisms of action
Isidro Sánchez García
FICUS
Cancer stem cells and cell therapy
Felipe X. Pimentel
Cell death and cancer. Atypical cell death pathways
CLINICAL RESEARCH TEAMS
Juan Jesús Cruz
Clinical and molecular analysis of solid tumors and hereditary cancer.
Clinical Oncology
Enrique de Álava
Molecular Pathology . Tumor Bank
Alberto Gómez Alonso
Clinical and molecular analysis of solid tumors and hereditary cancer.
Surgery
Alberto Orfao
Immunology and cancer. Molecular Diagnostic & Citometry
FICUS
Jesús San Miguel
Oncohematology.
Oncopharmacology. Novel drugs in haematological malignancies
CIC EMERGENT RESEACHERS
(ISCIII-Miguel Servet Researchers)
Azucena Esparís Ogando
Novel targets in breast cancer.
Mercedes Garayoa Berrueta
Bone marrow microenvironment and bone
lesions in multiple myeloma
Andres García Montero
Proteomic characterisation of chronic
lymphoproliferative T and NK syndromes.
FICUS
CIC EMERGENT RESEACHERS
(Ramón y Cajal Program, PCD)
Julia Almeida
Phenotypic , molecular and
functional characterization of the
tumor hematological TNK mature
cells.
Mercedes Dosil
Control of ribosomal biogenesis.
Coupling between ribosomal
biogenesis and signalling /
oncogenic pathways.
Maria Sacristan
Regulatory mechanisms in
mitotic exit in human cells.
FICUS
Alberto Fdez Medarde
Analysis of the functional specificity of
guanine nucleotide exchangers for
Ras, Grf1 and Grf2.
Carmen Guerrero
Study of the functional role of C3G in
signal transduction and its possible
implication in chronic myeloid
leukaemia.
SOCIO-SANITARY SERVICE UNITS
Genomics and Proteomics Unit, Bioinformatics
Directors: Drs. X. R. Bustelo J. De Las Rivas
Molecular, Cellular, and Cytogenetic Services
Director: Drs. J. San Miguel and A. Orfao
rticcc
G&P
Early Diagnosis Program and Genetic Counseling
Director: Drs. R. Sarmiento and J.J. Cruz
Traslational Oncopharmacology
Director: Dr. Atanasio Pandiella
Tumour Bank and Molecular Pathology Units
Director: Dr. E. de Álava
FICUS
National DNA Bank
Director: Drs. A. Orfao and E. de Álava
Graduate Program, CME, Scientific diffusion, Information to patients,
advocacy E.Santos
RESEARCH LINES: SCIENTIFIC
NETWORKING ESTABLISHED
TUMOR BANK
GENOM&PROT
NEW THERAPIES
TUMOR REGISTRY
NATIONAL
COORDINATION
MOL. DIAGNOSTICS
ANIMAL MODELS
BIOINFORMATICS
EDUCATION & TRAINING
FICUS
bancoadn
RED TEMATICA DE INVESTIGACION
COOPERATIVA EN CANCER (RTICC)
2007-2011
GR:2
GCA:2
GR:3
GCA: 1
GR:6
GCA:1
GR:1
GCA:1
GR: 24
GCA: 4
GR: 8
GCA: 0
GR:14
GCA:2
GR:6
GCA:1
GCA: 1
FICUS
GR:4
GCA:1
• 82 Grupos
regulares
• 21 Grupos
clínicos
asistenciales
4 Líneas verticales ● 6 Programas horizontales
● 13 CC.AA.
● - 5 M € / año
Coordinada desde el CIC de Salamanca
Financiación
USAL
CSIC
OTHER SOURCES
FICUS
Financiación
FUNDING, IBMCC - 1999/2004
"Fixed"
Institutional
support (CSIC,
USAL); 1% "Other" support ;
10%
Competitive.
Individual
Projects; 50%
FICUS
Competitive.
Collective
Projects; 39%
Financiación
Financiación
Nacional: MICINN, ISCIII
Regional: CYL
Nacional privada: AECC, Ramón Areces, otras.
Europea: Programa Marco
USA: privada (MMRF, IMF), NIH
FICUS
Industria: Nacional e Internacional